People · Operator
Named in public records as an officer, director or promoter · active 2017–2021 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2017 |
| Novata, Inc. | — | Other Technology | Series B | $20.7M | $396.2M | 2021 |
Scott Kennedy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott Kennedy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Errik Anderson | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| Philip Ferneau | 1 | 6 |
| Claudio Nessi | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Colin Greenspon | 1 | 3 |
| Erik Hirsch | 1 | 2 |
| Jonathan Sheller | 1 | 2 |
| Kevin Issett | 1 | 1 |
| Jon Sheller | 1 | 1 |
| Warren Kett | 1 | 1 |
| Tasha Matharu | 1 | 1 |
| Pavani Thagirisa | 1 | 1 |
| Christina Alfonso-Ercan | 1 | 1 |
| Chris Jurgens | 1 | 1 |
| Alexander Friedman | 1 | 1 |
| Kevin Isett | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.